Acceleron is dedicated to the discovery and development of innovative, life-changing medicines for patients with a wide range of serious and rare diseases. Our research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the body’s remarkable capacity for cellular growth and repair. Our approach to drug discovery is driven by deep scientific expertise—and an urgency to deliver effective treatments to thousands of patients who have few or no therapeutic options. The Company’s lead product candidate, luspatercept—an erythroid maturation agent—is being evaluated in two Phase 3 trials in a global partnership with Celgene to treat chronic, sometimes debilitating anemias in myelodysplastic syndromes (MDS) and beta-thalassemia. Acceleron is also advancing a neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with a Phase 2 trial of sotatercept initiated in pulmonary arterial hypertension (PAH). Acceleron has ongoing preclinical research efforts targeting additional indications in these three disease areas where there is a significantly high, unmet medical need.